Henrietta Lacks, HeLa Cells, and the Consent Problem in Tissue Research

In 2013 a research team published the complete genome of a woman who died in 1951, and her descendants found out from the news. The woman was Henrietta Lacks, whose tumor cells became HeLa, the first human cell line that would grow indefinitely in the laboratory. That single episode, more than sixty years after the cells were taken, is the clearest way to see what the HeLa story actually teaches: a consent form signed for one clinic visit cannot govern material that can be copied, sequenced, and shared forever. The agreement the National Institutes of Health reached with the Lacks family later that year did not decide who owns the cells. It did something more unusual. It turned consent from a signature into a standing relationship.

Key points#

• HeLa cells were removed from Henrietta Lacks at Johns Hopkins in 1951, without her knowledge, under the rules that governed research at the time.
• A genome is not just a tissue sample. It carries inherited information about a person's living relatives, so publishing it exposes the whole family.
• The 2013 NIH-Lacks agreement placed HeLa genome data in a controlled-access database and gave two family members a seat on the committee that reviews requests for it.
• The arrangement governs access; it does not resolve ownership, which U.S. law still leaves largely with institutions rather than donors.

A sample that outlived its moment#

Henrietta Lacks was a 31-year-old Black woman treated for cervical cancer at Johns Hopkins Hospital in 1951. During her care, clinicians took pieces of her tumor and of nearby healthy tissue and gave them to the researcher George Gey. Where other samples died within days, hers kept dividing. She was never told the cells had been kept, and she died on 4 October 1951. Her family learned that HeLa had spread through laboratories worldwide only in the 1970s.

The uncomfortable part is that none of this broke the rules of the era. Informed consent for research was not yet a legal requirement in the United States. The Nuremberg Code dated from 1947, but the domestic framework for protecting human subjects, the Belmont Report and what became the Common Rule, would not arrive for decades. So HeLa is not simply a story about one hospital behaving badly. It is a case study in how a routine practice becomes indefensible once the science, and the material, keep going long after the moment of consent has passed.

Why a genome changes everything#

For most of HeLa's history the ethical argument was about the tissue itself and about recognition for a family that had received neither. Then the nature of the data changed. When a European group sequenced and openly posted the full HeLa genome in March 2013, again without asking the family, the problem became something a tissue sample had never been.

A genome is relational. It encodes inherited variants shared with children, grandchildren, and cousins, including probabilistic hints about disease risk. Publishing Henrietta Lacks's genome effectively published private information about her living descendants, none of whom had been asked. After the family objected, the sequence was pulled from the public database. The lesson landed hard: de-identification cannot shield relatives when the donor's name is one of the best known in biology, and consent obtained (or not obtained) from one person can never speak for an entire lineage.

What the 2013 agreement actually did#

On 7 August 2013 the NIH announced terms it had negotiated directly with the Lacks family. Writing in Nature, Kathy Hudson and NIH Director Francis Collins laid them out. HeLa whole-genome data produced with NIH funding would go into a controlled-access repository, dbGaP, rather than onto the open internet. Researchers who want the data have to apply, and each request is reviewed by a HeLa Genome Data Access Working Group that seats two Lacks family members alongside scientists and bioethicists. Approved users promise to use the data only for biomedical research, to declare any commercial plans, and to credit the family in what they publish.

A 2024 NIH notice (NOT-OD-24-098) folded these expectations into the agency's wider Data Management and Sharing Policy without loosening them: deposit HeLa genome data to the designated controlled-access study, apply for access, and acknowledge Mrs. Henrietta Lacks and her family. The mechanism has now run for more than a decade.

The conceptual shift is easy to state and easy to underestimate. Consent stopped being a single yes or no and became participation in an ongoing decision. The family did not sign a form; they took a seat at the table. That is a deliberately narrow remedy. It covers only NIH-funded HeLa genome data, not the physical cells and not the many HeLa stocks already circulating in freezers around the world. What it demonstrates is something a one-page consent form structurally cannot: a durable link between a research enterprise and the specific people a dataset can identify.

The ownership question it left open#

The agreement stepped around ownership on purpose, because the law gives it almost nothing to stand on. In the United States you generally do not retain a property interest in tissue once it leaves your body. In Moore v. Regents of the University of California (1990), the California Supreme Court held that a patient had no ownership claim over cells that were removed during treatment and later commercialized. With property off the table, governance was the only lever left to pull.

That unresolved question resurfaced in court. In 2021 the Lacks estate sued a laboratory-supply company, arguing it had been unjustly enriched by selling HeLa products, and the parties reached a confidential settlement in 2023, as reported by outlets including CNN and the Associated Press. A private settlement is not a legal rule. It does not establish that families own cell lines. It does signal that the commercialization dispute the 2013 agreement set aside is still very much alive.

What this means for tissue research today#

The through-line is straightforward. Consent cannot be a single event when the material can be immortalized, sequenced, and shared without end. The tools that modern research reaches for grow directly out of this history: broad consent for unspecified future use, tiered data-access committees, benefit-sharing arrangements, and named acknowledgment of donors. None of these erases the tension between open science and the interests of identifiable people. They manage it, which is exactly what the NIH-Lacks arrangement was built to do.

HeLa cells helped advance the polio vaccine, cancer biology, and much of modern cell science. Honoring that contribution does not require pretending consent was ever obtained. It requires building systems, as the family and the NIH eventually did, in which the people behind a sample keep a voice long after the sample is gone.